Merck’s Efinopegdutide Resolved Fatty Liver Disease MASH in Up to 63% of Patients in Phase 2b Biopsy Trial

Merck’s experimental weekly injection efinopegdutide resolved MASH on biopsy in up to 63% of patients after 52 weeks, though long-term benefits and regulatory approval remain unproven.